Madrigal Pharmaceuticals Reports the Results of Resmetirom in P-III Trial for the Treatment of NASH Patients
Shots:
- The P-III (MAESTRO-NASH) trial evaluates resmetirom (80 & 100mg, BID) vs PBO in patients (n=966) with biopsy-confirmed NASH & a fibrosis stage of F1B, F2, or F3to F4. The 1EPs were NASH resolution at wk52 with no worsening of fibrosis & a reduction in fibrosis
- As per results, NASH resolution was achieved in 25.9% & 29.9% vs 9.7% of patients, reduction in fibrosis was seen in 24.2% & 25.9% vs 14.2% of patients & a 13.6% change in LDL cholesterol levels from baseline to wk24 was seen. The results were published in the New England Journal of Medicine
- The study also met its 2EPs of reduction in liver enzymes (ALT, AST and GGT) from baseline & reductions in atherogenic lipids, lipoproteins, fibrosis biomarkers & imaging tests
Ref: Madrigal | Image: Madrigal
Related News:- Madrigal Reports Results of Resmetirom in P-III (MAESTRO-NAFLD-1) Study for the Treatment of Non-Alcoholic Steatohepatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
